Status:
RECRUITING
Montelukast in Parkinson Disease
Lead Sponsor:
Mostafa Bahaa
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of b...
Detailed Description
Leukotrienes are along with prostaglandins, lipoxins, and thromboxanes included in a group of long-chain fatty acids known as eicosanoids. They are known to play important parts in the inflammatory re...
Eligibility Criteria
Inclusion
- \- Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa
Exclusion
- \- Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications
Key Trial Info
Start Date :
November 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06113640
Start Date
November 5 2023
End Date
December 20 2025
Last Update
January 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Mansoura University
Al Mansurah, Egypt, 35511